Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study
Retrospective analysis shows improved long-term outcomes in AYA patients with essential thrombocythemia, highlighting distinct clinical features and genetic profiles.
Key Points
AYA patients with essential thrombocythemia exhibited superior overall survival of 98.2% versus 90.1% in non-AYA counterparts.
Long-term outcomes demonstrated lower rates of JAK2V617F in AYA patients compared to non-AYA, with differences in other non-driver mutations.
Observational analysis across multiple centers examined clinical features and genetic profiles based on next-generation sequencing.
Findings suggest crucial age-related differences in myeloproliferative neoplasms, informing the need for targeted therapies.